Second Primary Lung Cancer Cohort Study (SPORT) — SPORT  

Lung Cancer Clinical Trial

Official title: Second Primary Lung Cancer Cohort Study (SPORT)

Status Recruiting

Clinical Trial Summary

Patients who have had curative treatment for lung cancer are at an increased risk of developing second primary lung cancers (and other cancers) over the next 10 years. Doctors need to develop better ways of monitoring patients during follow up so we can intervene as quickly as possible with further treatments. Measuring DNA in the blood which has come from the tumour, so called circulating tumour DNA (ctDNA), may be one way to do this.

Clinical Trial Description

This is a multi-centre, observational basic science study to follow patient who have undergone radical treatment, surgery or radiotherapy for Non-small Cell Lung Cancer (NSCLC) between two and five years previously. Following consent, participants will be asked to provide blood samples every six months for up to the next five years. Information from their routine clinical care, including information from any imaging, diagnostic tissue samples and blood tests will be collected. We will also request access to any original surplus diagnostic material, as well as future, excess tissue from diagnostic samples.

Blood samples will be analysed using various new scientific techniques looking to correlate emergence of new primary cancer (or recurrence of original NSCLC) with blood based markers. ;

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

• NCT number: NCT04178889
• Study type: Observational
• Source: Papworth Hospital NHS Foundation Trust
• Contact: Robert Rintoul, PhD FRCP
• Phone: 01223 639638
• Email: robert.rintoul@nhs.net
• Status: Recruiting
• Start date: January 1, 2020
• Completion date: December 2024